# Radiation Oncology/Prostate/Guidelines

* Front Page: Radiation Oncology | RTOG Trials | Randomized Trials
Prostate Cancer Guidelines

## General

* NCCN: Prostate Cancer
** Guideline link
* NCI: Health Professional PDQ
** Guideline link
* ACR: Prostate Main Page
** Guideline link
* AUA: Clinically Localized Prostate Cancer
** Guideline link
** 2007 PMID 17509297 -- "Guideline for the management of clinically localized prostate cancer: 2007 update." (Thompson I, J Urol. 2007 Jun;177(6):2106-31.)
* NICE: Summary of NICE guidance
** Guideline link
** 2008 PMID 18340076 -- "Diagnosis and treatment of prostate cancer: summary of NICE guidance." (Graham J, BMJ. 2008 Mar 15;336(7644):610-2.)
* EAU: European Association of Urology
** 2012 PDF Website "Guidelines on Prostate Cancer"
* ESMO: European Society for Medical Oncology
** 2012 PMID 23303340 link -- "Prostate cancer: ESMO Consensus Conference Guidelines 2012"

## Screening

* ACS: Prostate Cancer: Early Detection
** Guideline link
** 2010 PMID 20200110 -- "American Cancer Society guideline for the early detection of prostate cancer: update 2010." (Wolf AM, CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. Epub 2010 Mar 3.)

## Pretreatment Staging

* ACR: Pretreatment Staging
** Guideline link

## General Radiation Therapy

* German S3: Localized and Locally Advanced Prostate Cancer
** 2010 PMID 20180061 -- "[Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer] [Article in German]" (Bohmer D, Urologe A. 2010 Feb;49(2):211-5.)
* German S3: Postoperative Radiation Therapy and Brachytherapy
** 2010 PMID 20180062 -- "[Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy] [Article in German]" (Martin T, Urologe A. 2010 Feb;49(2):216-20.)
* ACR: Definitive EBRT for Stage T1-T2
** Guideline link
* ACR: EBRT Treatment Planning
** Guideline link

## Hormonal Therapy

* ASCO:
** 2006 PMID 17404365 -- Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
** 2004 PMID 15184404 -- American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

## Locally Advanced Prostate Cancer

* ACR: Locally Advanced Prostate Cancer
** Guideline link

## Node Positive Prostate Cancer

* ACR: Node Positive Prostate Cancer
** Guideline link

## Adjuvant RT

* ACR: Post-Radical Prostatectomy Radiation
** Guideline link

## Salvage RT

* ASTRO: Guidelines for re-biopsy and rising PSA after RP
** 1999 PMID 10561174 Full text -- Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy

## Active Surveillance

* ASCO / Cancer Care Ontario
** 2016 PMID 26884580 -- "Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement." (Chen R, J Clin Oncol. 2016 Feb 16 -- online ahead of print)

## Permanent Brachytherapy

* ACR: Permanent Source Brachytherapy
** Guideline link
** 2010 PMID 21106306 -- "American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer." (Rosenthal SA, Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):335-41. Epub 2010 Nov 23.)
* ABS: Low dose-rate guidelines
** Guideline link (may be out of date)
** 2012 PMID 22265434 -- "American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy."
** Morbidity; 2002 PMID 12243823 — "American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy." (Nag S et al. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):462-70.)
** $^{103}$Pd; 2000 PMID 10802349 — "American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society." (Beyer D et al. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):273-5.)
** Postimplant Dosimetry; 2000 PMID 10656396 — "The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis." (Nag S et al. Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):221-30.)
** Transperineal; 1999 PMID 10386635 — "American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer." (Nag S et al. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99.)
* ABS: High dose-rate guidelines
** Guideline link (may be out of date)
** 2012 PMID 22265435 -- "American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy."
* Cesium Advisory Group: Permanent prostate brachytherapy with Cs-131
** Cesium; 2008 PMID 18782682 -- "Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group." (Bice WS, Brachytherapy. 2008 Oct-Dec;7(4):290-6. Epub 2008 Sep 7.)
* NICE: Low dose-rate brachytherapy
** Guideline link

## Contouring

* RTOG: Pelvic LN Atlas
** Guideline link
* RTOG: Post-op Volumes
** Post-Op Contouring Atlas (PMID 19394158)

## Cryotherapy

* NICE: Cryotherapy
** Guideline link

## High-intensity focused ultrasound

* NICE: HIFU guidance
** Guideline link

## Hormone refractory prostate cancer

* NICE: HRPC guidance
** Guideline link

## Toxicity

* AUA: Erectile dysfunction
** Guideline link
* NICE: Erectile dysfunction
** Guideline link